Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.
Identifieur interne : 002415 ( Main/Exploration ); précédent : 002414; suivant : 002416Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.
Auteurs :Source :
- Bulletin of the World Health Organization [ 0042-9686 ] ; 1985.
Descripteurs français
- KwdFr :
- MESH :
- analogues et dérivés : Adamantane.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Amantadine, Rimantadine.
- Humains, Virus de la grippe A.
English descriptors
- KwdEn :
- MESH :
- chemical , analogs & derivatives : Adamantane.
- chemical , therapeutic use : Amantadine, Rimantadine.
- drug therapy : Influenza, Human.
- Humans, Influenza A virus.
Abstract
Amantadine (1-adamantanamine hydrochloride), an anti-influenza drug, effectively inhibits the replication of all human subtypes of influenza A virus (H1N1, H2N2 and H3N2) both in laboratory studies and in a variety of clinical situations in young and old persons. So far, it has been used on a relatively limited scale by community and hospital clinicians, partly because of concern over mild side-effects in approximately 6% of persons. The related compound, rimantadine (alpha-methyl-1-adamantane-methylamine hydrochloride), shows comparable antiviral activity with few or no side-effects. Although the mode of antiviral action is considered to be similar, the two drugs differ in their metabolic and pharmacological properties.Both amantadine and rimantadine have therapeutic uses and shorten the duration of influenza-A-induced fever, malaise, and virus shedding. A dosage of 200 mg of either drug for a 3-5-day period is effective but treatment has to commence on the first day of symptoms. Prophylaxis, particularly using rimantadine, could be usefully initiated in elderly and other high-risk individuals living in institutions and in the general community.
PubMed: 3872736
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000512
- to stream PubMed, to step Curation: 000512
- to stream PubMed, to step Checkpoint: 000448
- to stream Ncbi, to step Merge: 001087
- to stream Ncbi, to step Curation: 001087
- to stream Ncbi, to step Checkpoint: 001087
- to stream Main, to step Merge: 002534
- to stream Main, to step Curation: 002415
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.</title></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1985">1985</date><idno type="RBID">pubmed:3872736</idno><idno type="pmid">3872736</idno><idno type="wicri:Area/PubMed/Corpus">000512</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000512</idno><idno type="wicri:Area/PubMed/Curation">000512</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000512</idno><idno type="wicri:Area/PubMed/Checkpoint">000448</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000448</idno><idno type="wicri:Area/Ncbi/Merge">001087</idno><idno type="wicri:Area/Ncbi/Curation">001087</idno><idno type="wicri:Area/Ncbi/Checkpoint">001087</idno><idno type="wicri:Area/Main/Merge">002534</idno><idno type="wicri:Area/Main/Curation">002415</idno><idno type="wicri:Area/Main/Exploration">002415</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.</title></analytic><series><title level="j">Bulletin of the World Health Organization</title><idno type="ISSN">0042-9686</idno><imprint><date when="1985" type="published">1985</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adamantane (analogs & derivatives)</term><term>Amantadine (therapeutic use)</term><term>Humans</term><term>Influenza A virus</term><term>Influenza, Human (drug therapy)</term><term>Rimantadine (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adamantane (analogues et dérivés)</term><term>Amantadine (usage thérapeutique)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Humains</term><term>Rimantadine (usage thérapeutique)</term><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adamantane</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amantadine</term><term>Rimantadine</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Adamantane</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Amantadine</term><term>Rimantadine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Influenza A virus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Virus de la grippe A</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Amantadine (1-adamantanamine hydrochloride), an anti-influenza drug, effectively inhibits the replication of all human subtypes of influenza A virus (H1N1, H2N2 and H3N2) both in laboratory studies and in a variety of clinical situations in young and old persons. So far, it has been used on a relatively limited scale by community and hospital clinicians, partly because of concern over mild side-effects in approximately 6% of persons. The related compound, rimantadine (alpha-methyl-1-adamantane-methylamine hydrochloride), shows comparable antiviral activity with few or no side-effects. Although the mode of antiviral action is considered to be similar, the two drugs differ in their metabolic and pharmacological properties.Both amantadine and rimantadine have therapeutic uses and shorten the duration of influenza-A-induced fever, malaise, and virus shedding. A dosage of 200 mg of either drug for a 3-5-day period is effective but treatment has to commence on the first day of symptoms. Prophylaxis, particularly using rimantadine, could be usefully initiated in elderly and other high-risk individuals living in institutions and in the general community.</div></front></TEI><affiliations><list></list><tree></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002415 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002415 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:3872736
|texte= Current status of amantadine and rimantadine as anti-influenza-A agents: memorandum from a WHO meeting.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:3872736" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |